ZA931447B - Anti-tumour compounds. - Google Patents

Anti-tumour compounds.

Info

Publication number
ZA931447B
ZA931447B ZA931447A ZA931447A ZA931447B ZA 931447 B ZA931447 B ZA 931447B ZA 931447 A ZA931447 A ZA 931447A ZA 931447 A ZA931447 A ZA 931447A ZA 931447 B ZA931447 B ZA 931447B
Authority
ZA
South Africa
Prior art keywords
alkyl
quinazoline
pharmaceutically
hydrogen
tumour compounds
Prior art date
Application number
ZA931447A
Other languages
English (en)
Inventor
Stephen John Pegg
James Michael Wardleworth
Original Assignee
Zeneca Ltd
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, British Tech Group filed Critical Zeneca Ltd
Publication of ZA931447B publication Critical patent/ZA931447B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
  • Golf Clubs (AREA)
ZA931447A 1992-03-11 1993-03-01 Anti-tumour compounds. ZA931447B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929205320A GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds

Publications (1)

Publication Number Publication Date
ZA931447B true ZA931447B (en) 1993-09-13

Family

ID=10711936

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931447A ZA931447B (en) 1992-03-11 1993-03-01 Anti-tumour compounds.

Country Status (22)

Country Link
US (1) US5955463A (xx)
EP (1) EP0562734B1 (xx)
JP (1) JP3160111B2 (xx)
KR (1) KR100221011B1 (xx)
AT (1) ATE131823T1 (xx)
AU (1) AU659277B2 (xx)
CA (1) CA2090942C (xx)
CZ (1) CZ281811B6 (xx)
DE (1) DE69301048T2 (xx)
DK (1) DK0562734T3 (xx)
ES (1) ES2081178T3 (xx)
FI (1) FI108793B (xx)
GB (2) GB9205320D0 (xx)
GR (1) GR3018501T3 (xx)
HK (1) HK21297A (xx)
HU (1) HU211127A9 (xx)
IL (1) IL104984A (xx)
NO (1) NO301543B1 (xx)
NZ (1) NZ247122A (xx)
RU (1) RU2111209C1 (xx)
TW (1) TW223635B (xx)
ZA (1) ZA931447B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
AU5984296A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Quinazolines and pharmaceutical compositions
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
AU2237899A (en) 1998-01-21 1999-08-09 Sugen, Inc. Human orthologues of wart
WO1999053036A2 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6235213B1 (en) * 1998-05-18 2001-05-22 Micron Technology, Inc. Etching methods, methods of removing portions of material, and methods of forming silicon nitride spacers
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP2003512838A (ja) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー ショウジョウバエgタンパク質結合レセプター、核酸、およびそれに関連する方法。
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
EP2332962A1 (en) 2001-08-31 2011-06-15 BTG International Limited Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions
ATE526028T1 (de) 2001-08-31 2011-10-15 Btg Int Ltd Verwendung von cyclopentaägüchinazoline-derivaten zur krebsbehandlung
GB0317631D0 (en) * 2003-07-28 2003-08-27 Btg Int Ltd Synthetic method
KR101371773B1 (ko) 2005-12-15 2014-03-07 아스트라제네카 아베 암 치료를 위한, 안지오포이에틴-2 길항자와 vegf-a,kdr 및/또는 flt1 길항자의 조합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2065653B (en) * 1979-12-19 1983-03-09 Nat Res Dev Anti-cancer quinazoline derivatives
JPS5692876A (en) * 1979-12-19 1981-07-27 Nat Res Dev Anticancerous quinazoline derivative
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4725687A (en) * 1986-04-28 1988-02-16 Southern Research Institute 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
US4999424A (en) * 1988-11-10 1991-03-12 The Pennsylvania State University GAR transformylase inhibitor
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
ZA913730B (en) * 1990-05-30 1992-02-26 Ici Plc Anti-tumor compounds
US5145854A (en) * 1991-11-27 1992-09-08 Nair Madhavan G 1-formyl-5,8,10-trideazafolates

Also Published As

Publication number Publication date
FI931067A (fi) 1993-09-12
NO930881D0 (no) 1993-03-10
JP3160111B2 (ja) 2001-04-23
EP0562734A1 (en) 1993-09-29
KR930019667A (ko) 1993-10-18
DK0562734T3 (da) 1996-05-06
HU211127A9 (en) 1995-10-30
ATE131823T1 (de) 1996-01-15
GB2264946B (en) 1995-05-17
EP0562734B1 (en) 1995-12-20
DE69301048T2 (de) 1996-05-15
DE69301048D1 (de) 1996-02-01
TW223635B (xx) 1994-05-11
RU2111209C1 (ru) 1998-05-20
NZ247122A (en) 1995-07-26
ES2081178T3 (es) 1996-02-16
GB9205320D0 (en) 1992-04-22
CZ36293A3 (en) 1994-01-19
AU3378293A (en) 1993-09-16
CA2090942A1 (en) 1993-09-12
FI108793B (fi) 2002-03-28
NO301543B1 (no) 1997-11-10
GR3018501T3 (en) 1996-03-31
NO930881L (no) 1993-09-13
KR100221011B1 (ko) 1999-09-15
FI931067A0 (fi) 1993-03-10
IL104984A (en) 1998-01-04
AU659277B2 (en) 1995-05-11
CZ281811B6 (cs) 1997-02-12
GB2264946A (en) 1993-09-15
CA2090942C (en) 2000-02-08
GB9304807D0 (en) 1993-04-28
JPH06279438A (ja) 1994-10-04
HK21297A (en) 1997-02-27
US5955463A (en) 1999-09-21
IL104984A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
GB2264946B (en) Anti-tumour compounds
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HU9401974D0 (en) New intermediates for producing 9-[(substituted glicyl)-amido]-6-demetyl-6-deoxy-tetracyclines and pharmaceutical compositions containing them
AU679859B2 (en) Novel compound, process for producing the same, and antitumor agent
ES548418A0 (es) Un procedimiento para preparar un compuesto de piperazina
HK1019878A1 (en) Total synthesis of antitumor acylfulvenes.
FI943508A0 (fi) Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
AU1507888A (en) New bicyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
DE69129790D1 (de) 5-Amino-5,6,7,8-Tetrahydrochinoline und verwandte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GR3019145T3 (en) Fungicidal furanone derivatives
HU901377D0 (en) Process for preparation of carbamates
ATE189813T1 (de) Prostaglandin-i-analoga
GR3004321T3 (xx)
TW258661B (xx)
GR3001003T3 (en) Novel pregnane derivatives, processes for their preparaton and pharmaceutical compositions containing same
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.